Data from Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—A Comparison with the General Population

• DOI: 10.1158/1055-9965.c.7209244
• Publication Date: 2024-05-01T14:15:26Z
• Authors: Juho Pylväläinen; Jaakko Hoffström; Anu Kenttämies; Anssi Auvinen; Tuomas Mirtti; Antti Rannikko

<div>AbstractBackground:<p>We compare the risk of clinically significant (csPCa; ISUP Grade Group ≥ 2) and insignificant prostate cancer (isPCa; 1) in men with a nonsuspicious MRI (nMRI; PI-RADS ≤ general population, assess value PSA density (PSAD) stratification.</p>Methods:<p>In this retrospective population-based cohort study we identified 1,682 50–79-year-old men, who underwent nMRI at HUS (2016–2019). We compared their age-standardized incidence rates (IR) csPCa odds isPCa to local age- sex-matched population (<i>n</i> = 230,458) during six-year follow-up. Comparisons were performed by calculating rate ratios (IRR) ORs 95% confidence intervals (CI). repeated comparison for 920 PSAD < 0.15 ng/mL/cm<sup>3</sup>.</p>Results:<p>Compared IR was significantly higher after [1,852 vs. 552 per 100,000 person-years; IRR 3.4 (95% CI, 2.8–4.1)]. However, substantially lower if low [778 1.4 0.9–2.0)]. 2.4 1.7–3.5) all 5.0 2.8–9.1) low.</p>Conclusions:<p>Compared is not negligible nMRI. <0.15 ng/mL/cm<sup>3</sup> have worse harm-benefit balance than population.</p>Impact:<p>Prostate biopsies should be reserved cases indicated additional stratification.</p><p><i><a href="https://aacrjournals.org/cebp/article/doi/10.1158/1055-9965.EPI-24-0214" target="_blank">See related In Spotlight, p. 641</a></i></p></div>